Optimer Pharmaceuticals Completes Enrollment In Second Prulifloxacin Phase 3 Clinical Trial

 04.09.2008 07:04   medicalnewstoday.com

Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced that the company has completed enrollment in the second of two planned phase 3 clinical trials evaluating the safety and efficacy of Prulifloxacin for the treatment of infectious diarrhea in travelers.

World Gastroenterology